Previous studies characterizing the neurophysiological effects of amyloid and tau pathology in animal models of AD pathology have identified several changes associated with alterations in theta-gamma coupling3–6, power spectrum changes7–9, presence of epileptiform activity10,11, network hyperactivity12,13 as well as tau-associated neuronal silencing14,15. The gene discussed is MAPT; the disease is Alzheimer disease.